Effects of omega-3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double-blind placebo-controlled randomized trial.
anxiety
cognitive impairments
depression
fatigue
fear of cancer recurrence
insomnia
omega-3
prostate cancer
randomized clinical trial
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
11
09
2023
received:
01
11
2022
accepted:
16
09
2023
medline:
23
10
2023
pubmed:
3
10
2023
entrez:
3
10
2023
Statut:
ppublish
Résumé
In the general population, a higher omega-3 polyunsaturated fatty acids intake is associated with lower levels of several psychological symptoms, especially depression. However, the existing evidence in cancer is equivocal. This phase IIB double-blind, placebo-controlled trial was aimed at comparing the effects of eicosapentaenoic acid monoacylglyceride (MAG-EPA) supplementation and high oleic acid sunflower oil (HOSO; placebo) on depression levels (primary outcome) and other symptoms (anxiety, fear of cancer recurrence, fatigue, insomnia, perceived cognitive impairments; secondary outcomes). Participants, recruited in a prostate cancer clinic, were randomized to MAG-EPA (3.75 g daily; n = 65) or HOSO (3.75 g daily; n = 65) for 1 year post-radical prostatectomy (RP), starting 4-10 weeks before surgery. Patients completed self-report scales at baseline (before RP) and 3, 6, 9, and 12 months after: Hospital Anxiety and Depression Scale (HADS), Fear of Cancer Recurrence Inventory (FCRI), Insomnia Severity Index (ISI), Fatigue Symptom Inventory (FSI), and Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog). Analyses showed significant reductions in HADS-depression, HADS-anxiety, FCRI, ISI, FSI-number of days, and FACT-Cog-impact scores over time. A significant group-by-time interaction was obtained on FACT-Cog-Impact scores only; yet, the temporal change was significant in HOSO patients only. Several symptoms significantly decreased over time, mainly within the first months of the study. However, MAG-EPA did not produce greater reductions than HOSO. Omega-3 supplementation does not seem to improve psychological symptoms of men treated with RP.
Sections du résumé
BACKGROUND
In the general population, a higher omega-3 polyunsaturated fatty acids intake is associated with lower levels of several psychological symptoms, especially depression. However, the existing evidence in cancer is equivocal.
METHODS
This phase IIB double-blind, placebo-controlled trial was aimed at comparing the effects of eicosapentaenoic acid monoacylglyceride (MAG-EPA) supplementation and high oleic acid sunflower oil (HOSO; placebo) on depression levels (primary outcome) and other symptoms (anxiety, fear of cancer recurrence, fatigue, insomnia, perceived cognitive impairments; secondary outcomes). Participants, recruited in a prostate cancer clinic, were randomized to MAG-EPA (3.75 g daily; n = 65) or HOSO (3.75 g daily; n = 65) for 1 year post-radical prostatectomy (RP), starting 4-10 weeks before surgery. Patients completed self-report scales at baseline (before RP) and 3, 6, 9, and 12 months after: Hospital Anxiety and Depression Scale (HADS), Fear of Cancer Recurrence Inventory (FCRI), Insomnia Severity Index (ISI), Fatigue Symptom Inventory (FSI), and Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog).
RESULTS
Analyses showed significant reductions in HADS-depression, HADS-anxiety, FCRI, ISI, FSI-number of days, and FACT-Cog-impact scores over time. A significant group-by-time interaction was obtained on FACT-Cog-Impact scores only; yet, the temporal change was significant in HOSO patients only.
CONCLUSIONS
Several symptoms significantly decreased over time, mainly within the first months of the study. However, MAG-EPA did not produce greater reductions than HOSO. Omega-3 supplementation does not seem to improve psychological symptoms of men treated with RP.
Identifiants
pubmed: 37787025
doi: 10.1002/cam4.6598
pmc: PMC10587967
doi:
Substances chimiques
Eicosapentaenoic Acid
AAN7QOV9EA
Banques de données
ClinicalTrials.gov
['NCT02333435']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20163-20176Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
BMJ Open. 2019 Jan 24;9(1):e026809
pubmed: 30679301
Nutrients. 2019 Jul 16;11(7):
pubmed: 31315273
Cancer Prev Res (Phila). 2014 Jul;7(7):766-76
pubmed: 24824038
Breast Cancer Res Treat. 2017 Jan;161(2):299-310
pubmed: 27913933
J Clin Psychiatry. 2013 Jul;74(7):732-8
pubmed: 23945451
Nutrients. 2023 Mar 11;15(6):
pubmed: 36986098
JAMA Netw Open. 2018 Sep 7;1(5):e182327
pubmed: 30646157
J Affect Disord. 2016 Nov 15;205:269-281
pubmed: 27544316
Br J Psychiatry. 2016 Sep;209(3):192-201
pubmed: 27103682
Nutrients. 2016 Mar 02;8(3):128
pubmed: 26950145
Nutr Cancer. 2007;59(1):14-20
pubmed: 17927497
Cochrane Database Syst Rev. 2021 Nov 24;11:CD004692
pubmed: 34817851
Proteomics. 2008 May;8(10):1965-74
pubmed: 18491311
Psychooncology. 2005 Jun;14(6):429-41
pubmed: 15376284
JNCI Cancer Spectr. 2019 Nov 29;4(1):pkz099
pubmed: 32064458
Qual Life Res. 1998 May;7(4):301-10
pubmed: 9610214
Acta Oncol. 2016 Jul;55(7):821-7
pubmed: 26935517
World J Oncol. 2019 Apr;10(2):63-89
pubmed: 31068988
J Affect Disord. 2019 Feb 15;245:1114-1118
pubmed: 30699854
J Am Coll Nutr. 2010 Dec;29(6):586-94
pubmed: 21677122
Cancer Med. 2023 Oct;12(19):20163-20176
pubmed: 37787025
J Nutr. 2013 Nov;143(11):1743-52
pubmed: 24005610
Brain Behav Immun. 2011 Nov;25(8):1725-34
pubmed: 21784145
Clin Nutr. 2014 Dec;33(6):1017-23
pubmed: 24746976
J Pers Assess. 1998 Dec;71(3):349-67
pubmed: 9933941
BMC Cancer. 2018 Jan 10;18(1):64
pubmed: 29321047
J Clin Med. 2016 Jul 27;5(8):
pubmed: 27472373
BMJ Open. 2014 Mar 13;4(3):e003901
pubmed: 24625637
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
J Psychosom Res. 2013 Apr;74(4):354-60
pubmed: 23497839
Cancer Res Treat. 2019 Apr;51(2):556-567
pubmed: 30011984
Sleep. 2018 Jan 1;41(1):
pubmed: 29165623
J Cancer Surviv. 2015 Sep;9(3):481-91
pubmed: 25603948
Prostaglandins Leukot Essent Fatty Acids. 2012 Apr;86(4-5):155-60
pubmed: 22472486
Support Care Cancer. 2020 Oct;28(10):4813-4824
pubmed: 31980895
Br J Cancer. 2005 Dec 12;93(12):1329-33
pubmed: 16306875
Breast Cancer Res Treat. 2017 Feb;161(3):391-398
pubmed: 27933449
J Genet Eng Biotechnol. 2022 Mar 16;20(1):48
pubmed: 35294666
Psychooncology. 2014 Feb;23(2):121-30
pubmed: 24105788
Support Care Cancer. 2013 Jun;21(6):1761-71
pubmed: 23455492
Eur J Cancer Care (Engl). 2017 Nov;26(6):
pubmed: 28169490
J Clin Oncol. 2011 Sep 10;29(26):3580-6
pubmed: 21825267
Asia Pac J Clin Oncol. 2020 Apr;16(2):e125-e130
pubmed: 31069946
Prostaglandins Leukot Essent Fatty Acids. 2018 Dec;139:9-13
pubmed: 30471773
JNCI Cancer Spectr. 2019 Jun;3(2):pkz005
pubmed: 31119206
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Nutr Hosp. 2019 Aug 26;36(4):939-949
pubmed: 31215788
Brain Behav Immun. 2012 Aug;26(6):988-95
pubmed: 22640930
Eur J Clin Nutr. 2009 Nov;63(11):1353-9
pubmed: 19623203
Transl Psychiatry. 2019 Aug 5;9(1):190
pubmed: 31383846
Br J Nutr. 2012 Jul;108(2):315-26
pubmed: 22136711
Breast Cancer Res. 2015 May 04;17:62
pubmed: 25936773
Support Care Cancer. 2009 Mar;17(3):241-51
pubmed: 18414902
J Pain Symptom Manage. 2008 Nov;36(5):480-7
pubmed: 18495413
Menopause. 2014 Apr;21(4):347-54
pubmed: 23982113